Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

It was because of slow recruitment. They released that reasoning that psoriasis trials are very competitive right now. So slow recruitment really amped up as they added 34 sites to make this move. They then had to many cohorts in progress to release interim data which could jeopardize the trial and make IPIX add additional patients which would have delayed the trial and added much more cost.

It’s real life here and BP is involved to help navigate. IPIX is making the right moves.